@article{431d7db579a241759bfb04f58160c9fe,
title = "Brain MRI after critical care admission: A longitudinal imaging study",
abstract = "Purpose: To investigate the association between episodes of critical care hospitalizations and delirium with structural brain changes in older adults. Materials and methods: We included Mayo Clinic Study of Aging participants ≥60 years old at the time of study enrollment (October 29, 2004, through September 11, 2017) with available brain MRI and {\textquoteleft}amyloid{\textquoteright} positron emission tomography (PET) scans. We tested the hypothesis that a) intensive care unit (ICU) admission is associated with greater cortical thinning and atrophy in entorhinal cortex, inferior temporal cortex, middle temporal cortex, and fusiform cortex (Alzheimer{\textquoteright}'s disease-signature regions); b) atrophy in hippocampus and corpus callosum; c) delirium accelerates these changes; and d) ICU admission is not associated with increased deposition of cortical amyloid. Results: ICU admission was associated with cortical thinning in temporal, frontal, and parietal cortices, and decreases in hippocampal/corpus callosum volumes, but not Alzheimer{\textquoteright}'s disease-signature regions. For hippocampal volume, and 10 of 14 cortical thickness measurements, the change following ICU admission was significantly more pronounced for those who experienced delirium. ICU admission was not associated with an increased amyloid burden. Conclusions: Critical care hospitalization is associated with accelerated brain atrophy in selected brain regions, without increases in amyloid deposition, suggesting a pathogenesis based on neurodegeneration unrelated to Alzheimer{\textquoteright}'s pathway.",
keywords = "AD-signature cortex, Corpus callosum, Cortical thinning, Hippocampus, Intensive care unit, Magnetic resonance imaging, Older adults",
author = "Juraj Sprung and Warner, {David O.} and Knopman, {David S.} and Petersen, {Ronald C.} and Mielke, {Michelle M.} and Jack, {Clifford R.} and Martin, {David P.} and Hanson, {Andrew C.} and Schroeder, {Darrell R.} and Przybelski, {Scott A.} and Schulte, {Phillip J.} and Laporta, {Mariana L.} and Weingarten, {Toby N.} and Prashanthi Vemuri",
note = "Funding Information: Dr. Knopman served on a Data Safety Monitoring Board for the DIAN study. He serves on a Data Safety Monitoring Board for a tau therapeutic for Biogen, but receives no personal compensation. He is an investigator in clinical trials sponsored by Biogen , Lilly Pharmaceuticals, and the University of Southern California . He serves as a consultant for Samus Therapeutics, Third Rock, and Alzeca Biosciences but receives no personal compensation. He receives research support from the NIH . Dr. Petersen is a consultant for Biogen, Inc., Roche, Inc., Merck, Inc., Genentech Inc., Eisai,Inc.; has given educational lectures for GE Healthcare, receives publishing royalties from Mild Cognitive Impairment ( Oxford University Press , 2003), UpToDate, and receives research support from the NIH / NIA . Dr. Jack serves on an independent data monitoring board for Roche and has served as a speaker for Eisai, but he receives no personal compensation from any commercial entity. He receives research support from NIH and the Alexander Family Alzheimer's Disease Research Professorship of the Mayo Clinic . Dr. Mielke consults for Brain Protection Company, receives an unrestricted research grant from Biogen , and receives funding from NIA / NIH . Dr. Weingarten currently serves as a consultant to Medtronic in the role as chairman of the Clinical Endpoint Committee for the Prodigy Trial; has received research support from Respiratory Motion and unrestricted investigator-initiated grants from Merck . Drs. Sprung, Schulte, Martin, Hanson, Schroeder, Przybelski, Laporta, Warner and Vemuri have nothing to disclose. Funding Information: This work was supported by NIH grants P50 AG016574 , P30 AG062677 , U01 AG006786 , R01 AG034676 , R01 AG41851 , and R37 AG11378 , the Elsie and Marvin Dekelboum Family Foundation , GHR Foundation , Alexander Family Alzheimer's Disease Research Professorship of the Mayo Clinic , Liston Award , Alzheimer's Association , Schuler Foundation and the Mayo Foundation for Medical Education and Research . Support is provided by the Rochester Epidemiology Project ( R01 AG034676 , PIs: WA Rocca and J St. Sauver) and the Mayo Clinic Center for Clinical and Translational Science (CTSA), grant number UL1 TR000135 from the National Center for Advancing Translational Sciences (NCATS). Funding Information: This work was supported by NIH grants P50 AG016574, P30 AG062677, U01 AG006786, R01 AG034676, R01 AG41851, and R37 AG11378, the Elsie and Marvin Dekelboum Family Foundation, GHR Foundation, Alexander Family Alzheimer's Disease Research Professorship of the Mayo Clinic, Liston Award, Alzheimer's Association, Schuler Foundation and the Mayo Foundation for Medical Education and Research. Support is provided by the Rochester Epidemiology Project (R01 AG034676, PIs: WA Rocca and J St. Sauver) and the Mayo Clinic Center for Clinical and Translational Science (CTSA), grant number UL1 TR000135 from the National Center for Advancing Translational Sciences (NCATS).Dr. Knopman served on a Data Safety Monitoring Board for the DIAN study. He serves on a Data Safety Monitoring Board for a tau therapeutic for Biogen, but receives no personal compensation. He is an investigator in clinical trials sponsored by Biogen, Lilly Pharmaceuticals, and the University of Southern California. He serves as a consultant for Samus Therapeutics, Third Rock, and Alzeca Biosciences but receives no personal compensation. He receives research support from the NIH. Dr. Petersen is a consultant for Biogen, Inc., Roche, Inc., Merck, Inc., Genentech Inc., Eisai,Inc.; has given educational lectures for GE Healthcare, receives publishing royalties from Mild Cognitive Impairment (Oxford University Press, 2003), UpToDate, and receives research support from the NIH/NIA. Dr. Jack serves on an independent data monitoring board for Roche and has served as a speaker for Eisai, but he receives no personal compensation from any commercial entity. He receives research support from NIH and the Alexander Family Alzheimer's Disease Research Professorship of the Mayo Clinic. Dr. Mielke consults for Brain Protection Company, receives an unrestricted research grant from Biogen, and receives funding from NIA/NIH. Dr. Weingarten currently serves as a consultant to Medtronic in the role as chairman of the Clinical Endpoint Committee for the Prodigy Trial; has received research support from Respiratory Motion and unrestricted investigator-initiated grants from Merck. Drs. Sprung, Schulte, Martin, Hanson, Schroeder, Przybelski, Laporta, Warner and Vemuri have nothing to disclose. Publisher Copyright: {\textcopyright} 2020 Elsevier Inc.",
year = "2021",
month = apr,
doi = "10.1016/j.jcrc.2020.11.024",
language = "English (US)",
volume = "62",
pages = "117--123",
journal = "Seminars in Anesthesia",
issn = "0883-9441",
publisher = "Elsevier BV",
}